A Phase I Study of Ultra Low Dose Interleukin-2 and Stem Cell Factor in Patients with HIV Infection or HIV and Cancer
Open Access
- 1 July 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (13) , 3993-3996
- https://doi.org/10.1158/1078-0432.ccr-06-0268
Abstract
Purpose: Ultra low doses of interleukin-2 (IL-2) can activate the high-affinity IL-2 receptor constitutively expressed on CD56bright natural killer (NK) cells, the CD34+ NK cell precursor, and CD4+CD25+ regulatory T cells (Tregs) in vivo. We have previously shown synergy between IL-2 and stem cell factor (SCF) in the generation of CD56bright NK cells from CD34+ hemopoietic progenitor cells in vitro and showed synergistic NK cell expansion in an in vivo preclinical model. To determine the safety, toxicity, and immune modulation of this combination of cytokines in vivo, we conducted a first-in-man phase I study.Keywords
This publication has 18 references indexed in Scilit:
- Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cellsNature Medicine, 2005
- In vivo expansion of CD4+CD45RO-CD25+ T cells expressing foxP3 in IL-2-treated HIV-infected patientsJournal of Clinical Investigation, 2005
- A Human CD34(+) Subset Resides in Lymph Nodes and Differentiates into CD56brightNatural Killer CellsImmunity, 2005
- Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T CellsThe Journal of Experimental Medicine, 2004
- CD25+CD4+ Regulatory T Cells from the Peripheral Blood of Asymptomatic HIV-infected Individuals Regulate CD4+ and CD8+ HIV-specific T Cell Immune Responses In Vitro and Are Associated with Favorable Clinical Markers of Disease StatusThe Journal of Experimental Medicine, 2004
- Control of Regulatory T Cell Development by the Transcription Factor Foxp3Science, 2003
- Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.Journal of Clinical Investigation, 1998
- Increases in CD4 T Lymphocytes with Intermittent Courses of Interleukin-2 in Patients with Human Immunodeficiency Virus Infection — A Preliminary StudyNew England Journal of Medicine, 1995
- Expression of a functional c-kit receptor on a subset of natural killer cells.The Journal of Experimental Medicine, 1993
- The role of natural killer cells in innate resistance to infectionCurrent Opinion in Immunology, 1993